CoChat

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program

Zeitler, Philip, Galindo, Rodolfo J., Davies, Melanie J., Bergman, Brandon K., Thieu, Vivian T., Nicolay, Claudia, Allen, Sheryl, Heine, Robert J., Lee, Clare J. · 2024 · Diabetes Care
Cited by 14

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS: This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS: At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P < 0.001) higher glycemic levels (8.5% vs. 8.2%, P < 0.001), higher BW (97 vs. 93 kg, P < 0.001) and BMI (35 vs. 34 kg/m2, P < 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (−2.6% vs. −2.4%), BW (−14 vs. −13 kg), WC (−10 vs. −10 cm), triglycerides (−26% vs. −24%), HDL (7% vs. 7%), and systolic BP (−6 vs. −7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS: Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc23-2356

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 18

  1. Viner, 2017, Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden, Lancet, 389, 2252, 10.1016/S0140-6736(17)31371-5 · DOI · Paper page
  2. Lawrence, 2021, Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017, JAMA, 326, 717, 10.1001/jama.2021.11165 · DOI · Paper page
  3. Lawrence, 2014, Incidence of diabetes in United States youth by diabetes type, race/ethnicity, and age, 2008–2009, Diabetes, 63, A407
  4. Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009, JAMA, 311, 1778, 10.1001/jama.2014.3201 · DOI · Paper page
  5. Sasidharan Pillai, 2023, Incidence, severity, and presentation of type 2 diabetes in youth during the first and second year of the COVID-19 pandemic, Diabetes Care, 46, 953, 10.2337/dc22-1702 · DOI
  6. Magge, 2022, The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes, J Pediatr, 251, 51, 10.1016/j.jpeds.2022.08.010 · DOI
  7. TODAY Study Group, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
  8. Lee, 2023, Earlier age at type 2 diabetes diagnosis is associated with increased genetic risk of cardiovascular disease, Diabetes Care, 46, 1085, 10.2337/dc22-2144 · DOI
  9. Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes, Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
  10. Emerging Risk Factors Collaboration, 2023, Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation, Lancet Diabetes Endocrinol, 11, 731, 10.1016/S2213-8587(23)00223-1 · DOI · Paper page
  11. Sargeant, 2020, Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials, Diabetologia, 63, 1516, 10.1007/s00125-020-05174-9 · DOI · Paper page
  12. Misra, 2023, Current insights and emerging trends in early-onset type 2 diabetes, Lancet Diabetes Endocrinol, 11, 768, 10.1016/S2213-8587(23)00225-5 · DOI · Paper page
  13. Rosenstock, 2021, Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial, Lancet, 398, 143, 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
  14. Utzschneider, 2021, Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study, Diabetes Res Clin Pract, 178, 108948, 10.1016/j.diabres.2021.108948 · DOI
  15. Sam, 2021, Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) study, Diabetes Care, 44, 1938, 10.2337/dc21-0027 · DOI
  16. TODAY Study Group, 2023, Effect of early glycemic control in youth-onset type 2 diabetes on longer-term glycemic control and β-cell function: results from the TODAY study, Diabetes Care, 46, 1507, 10.2337/dc23-0560 · DOI
  17. Zeitler, 2022, Deterioration of glycemic control in youth-onset type 2 diabetes: What are the early and late predictors, J Clin Endocrinol Metab, 107, e3384, 10.1210/clinem/dgac254 · DOI
  18. Klingensmith, 2016, Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience, Diabetes Care, 39, 122, 10.2337/dc15-1206 · DOI · Paper page

Cited by

See all 14

Metadata

Authors
Zeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J.
Affiliations
  • 1Children’s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO
  • 2University of Miami Miller School of Medicine, Miami, FL
  • 3Diabetes Research Centre, University of Leicester and the Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, U.K.
  • 4Eli Lilly and Company, Indianapolis, IN
Venue
Diabetes Care
Published
2024-04-19
Volume
47
Issue
6
Pages
1056-1064
ISSN
  • 0149-5992
  • 1935-5548
Cited by
14
References
18
Language
en
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. https://app.cochat.ai/papers/10.2337/dc23-2356
The paper
Zeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J. (2024). Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. https://doi.org/10.2337/dc23-2356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.